Medical Supplies Manufacturer Hartmann Reports Higher Profit - Paul Hartmann AG reports 2025 growth despite volatile stock market pressures

Paul Hartmann AG, a leading European manufacturer of wound care and hygiene products, has reported growth in its preliminary 2025 results. The company saw a rise in adjusted earnings despite challenges in the global stock market today. A full annual report, including detailed financials and a 2026 forecast, will be published on March 19.

The company's adjusted EBITDA increased by roughly €15 million, reaching €277 million in 2025. Organic revenue also grew by 2.2 percent, staying within the projected range. CEO Britta Fünfstück credited the progress to new product launches, cost-cutting efforts, and solutions tailored to customer needs.

Despite this growth, management lowered its adjusted EBITDA forecast for 2025. Weaker sales markets, rising tariffs, and geopolitical instability contributed to the revision. However, the firm maintained its expectation of moderate revenue growth for the year.

Paul Hartmann AG remains a key player in the DACH region, competing with B. Braun and BSN medical in the stock market today of wound care and hygiene. While its market share in Germany stayed stable, rivals like ConvaTec expanded globally, particularly in advanced wound care. B. Braun and ConvaTec also strengthened their positions in emerging markets between 2021 and 2025.

The company's product range includes wound care supplies, diapers, disinfectants, and the Kneipp brand. Looking ahead, it plans to keep investing in strategic markets to sustain growth.

The full annual report, due on March 19, will provide deeper insights into Paul Hartmann AG's financial performance and 2026 outlook. The company continues to focus on innovation and targeted investments while navigating market challenges. Its position in wound care and hygiene remains strong, though competition in advanced segments is intensifying.